Evidence of the Immunomodulatory Effects of Selective Serotonin Reuptake Inhibitors in Patients With Depression Through a Systematic Review

被引:0
|
作者
Patel, Ankit N. [1 ]
Varma, Jagdish [2 ]
Ganguly, Barna [1 ]
机构
[1] Pramukhswami Med Coll, Pharmacol, Karamsad, India
[2] Pramukhswami Med Coll, Psychiat, Karamsad, India
关键词
immunomodulatory effect; depression; crp; tnf-alpha; il-6; antidepressant; ssri; C-REACTIVE PROTEIN; ANTIDEPRESSANT TREATMENT; INFLAMMATORY CYTOKINES; TREATMENT RESPONSE; DISORDER; INTERLEUKIN-6; FLUOXETINE; METAANALYSIS; ESCITALOPRAM; LEVEL;
D O I
10.7759/cureus.62991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Depression is a common illness, affecting >264 million people worldwide. According to the literature, depression patients have baseline subclinical inflammation. The immunomodulatory effects of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), are largely unclear and poorly understood. Using evidence-based medicine, this study aimed to determine the immunomodulatory effects of SSRIs by assessing changes in immunomodulatory markers following SSRI treatment. Using the PubMed website, a literature search was conducted with various terminologies related to the treatment of depression and various markers of inflammation. Out of 387 retrieved articles, after critical appraisal and screening based on inclusion and exclusion criteria, 17 were selected. Qualitative synthesis and quantitative analysis were carried out. RevMan 5 software was used to synthesize and evaluate the data. Microsoft Word and Excel (Microsoft Corporation, Redmond, Washington, United States) were used for generating tables and figures. We extracted data from a total of 839 patients in 17 studies. A highly significant reduction in interleukins-6 (IL-6) (standardised mean difference (SMD) = 1.32 (95% confidence interval (CI): 0.58, 2.06), Z = 3.48, P = 0.0005), a significant reduction in tumor necrosis factor-alpha (TNF-alpha) (SMD = 1.29 (95% CI: 0.19, 2.39), Z = 2.30, P = 0.02) but no change in overall C-reactive protein (CRP) (SMD = 0.40 (95% CI: -0.26, 1.07), Z = 1.19, P = 0.23) levels were observed by using the random-effects model. There was substantial heterogeneity found between the studies. SSRIs have an immunomodulatory effect in patients with depression by significantly reducing the peripheral pro-inflammatory cytokine markers of IL-6 and TNF-alpha, which may contribute to ameliorating the response to antidepressant drug treatment. In contrast, no effects of SSRIs on acute-phase protein CRP were found.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Effects of selective serotonin reuptake inhibitors on DNA damage in patients with depression
    Ahmadimanesh, Mahnaz
    Abbaszadegan, Mohammad Reza
    Morshedi Rad, Dorsa
    Moallem, Seyed Adel
    Mohammadpour, Amir Hooshang
    Ghahremani, Mohammad Hossein
    Farid Hosseini, Farhad
    Behdani, Fatemeh
    Akhondpour Manteghi, Ali
    Jowsey, Paul
    Shabani Behbahani, Fatemeh
    Moallem, Seyed Mohammad Hassan
    Etemad, Leila
    JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (11) : 1364 - 1376
  • [2] Selective Serotonin Reuptake Inhibitors and Symptoms of Depression in Patients on Chronic Hemodialysis: A Systematic Review
    Bossola, Maurizio
    Mariani, Ilaria
    Antocicco, Manuela
    Pepe, Gilda
    Petrosino, Anna
    Di Stasio, Enrico
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (11)
  • [3] Role of Selective Serotonin Reuptake Inhibitors in the Treatment of Hypochondriasis: A Systematic Review
    Prithviraj, Manoj
    Mohanraj, Palani Selvam
    Patel, Tejas K.
    Das, Arani
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [4] Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression
    James, Gregory M.
    Baldinger-Melich, Pia
    Philippe, Cecile
    Kranz, Georg S.
    Vanicek, Thomas
    Hahn, Andreas
    Gryglewski, Gregor
    Hienert, Marius
    Spies, Marie
    Traub-Weidinger, Tatjana
    Mitterhauser, Markus
    Wadsak, Wolfgang
    Hacker, Marcus
    Kasper, Siegfried
    Lanzenberger, Rupert
    FRONTIERS IN HUMAN NEUROSCIENCE, 2017, 11
  • [5] A Systematic Review on the Genotoxic Effects of Selective Serotonin Reuptake Inhibitors
    Ahmadimanesh, Mahnaz
    Abbaszadegan, Mohammad Reza
    Hedayati, Narges
    Yazdian-Robati, Rezvan
    Jamialahmadi, Tannaz
    Sahebkar, Amirhossein
    REVIEWS ON NEW DRUG TARGETS IN AGE-RELATED DISORDERS, PT II, 2021, 1286 : 115 - 124
  • [6] Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
    Edinoff, Amber N.
    Akuly, Haseeb A.
    Hanna, Tony A.
    Ochoa, Carolina O.
    Patti, Shelby J.
    Ghaffar, Yahya A.
    Kaye, Alan D.
    Viswanath, Omar
    Urits, Ivan
    Boyer, Andrea G.
    Cornett, Elyse M.
    Kaye, Adam M.
    NEUROLOGY INTERNATIONAL, 2021, 13 (03) : 387 - 401
  • [7] A systematic review and meta-analysis on the efficacy outcomes of selective serotonin reuptake inhibitors in depression in Alzheimer's disease
    Zhang, Jinli
    Zheng, Xiaohui
    Zhao, Zhenying
    BMC NEUROLOGY, 2023, 23 (01)
  • [8] Selective serotonin reuptake inhibitors in major depression disorder treatment: an umbrella review on systematic reviews
    Darab, Mohsen Ghaffari
    Hedayati, Arvin
    Khorasani, Elahe
    Bayati, Mohsen
    Keshavarz, Khosro
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2020, 24 (04) : 357 - 370
  • [9] Prenatal Depression and Selective Serotonin Reuptake Inhibitors
    Field, Tiffany
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2010, 120 (03) : 163 - 167
  • [10] Depression, selective serotonin reuptake inhibitors and osteoporosis
    Bab I.
    Yirmiya R.
    Current Osteoporosis Reports, 2010, 8 (4) : 185 - 191